Tech Company Financing Transactions
Glycomine Funding Round
Glycomine closed a $12 million Series A funding round on 11/17/2016. Investors included Sanderling Ventures and Chiesi Ventures.
Transaction Overview
Company Name
Announced On
11/17/2016
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Series A
Investors
Sanderling Ventures (Lead Investor) (Peter McWilliams)
Chiesi Ventures (Giacomo Chiesi)
Proceeds Purpose
Glycomine will use the proceeds from this financing to complete IND enabling pre-clinical studies and initiate clinical studies of its substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (CDG-Ia), and to accelerate discovery efforts towards an enzyme replacement therapy for N-glycanase deficiency (Ngly1).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
733 Industrial Rd.
San Carlos, CA 94070
USA
San Carlos, CA 94070
USA
Phone
Website
Email Address
Overview
Glycomine is developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding for which no other therapeutic options exist.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter McWilliams
Chief Medical Officer
Horacio Plotkin
Vice President
Geoffrey Hird
VP - Regulatory Affairs
Lisa Koch-Hulle
Browse more venture capital transactions:
Prev: 11/17/2016: Mobalytics venture capital transaction
Next: 11/17/2016: analyticsMD venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs